Terms: = Ovarian cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Staging
11 results:
1. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in ovarian cancer.
Buehner TM; Liotta M; Potkul RK; Wagner RH; Savir-Baruch B
Mol Imaging Biol; 2024 Feb; 26(1):45-52. PubMed ID: 36754935
[TBL] [Abstract] [Full Text] [Related]
2. Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy.
Crombé A; Gauquelin L; Nougaret S; Chicart M; Pulido M; Floquet A; Guyon F; Croce S; Kind M; Cazeau AL
Diagn Interv Imaging; 2021 Oct; 102(10):629-639. PubMed ID: 34112625
[TBL] [Abstract] [Full Text] [Related]
3.
Dendl K; Koerber SA; Finck R; Mokoala KMG; Staudinger F; Schillings L; Heger U; Röhrich M; Kratochwil C; Sathekge M; Jäger D; Debus J; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4089-4100. PubMed ID: 34050777
[TBL] [Abstract] [Full Text] [Related]
4.
Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
[TBL] [Abstract] [Full Text] [Related]
5. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract] [Full Text] [Related]
6. Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study.
Farthmann J; Hasenburg A; Weil M; Fotopoulou C; Ewald-Riegler N; du Bois O; Trillsch F; Mahner S; Strauss HG; Wimberger P; Reuss A; du Bois A
Support Care Cancer; 2015 Jan; 23(1):117-23. PubMed ID: 24996831
[TBL] [Abstract] [Full Text] [Related]
7. Preoperative fluorine 18 fluorodeoxyglucose tumoral uptake ratio between upper and lower abdomen in primary advanced-stage ovarian cancer.
Shim SH; Kim DY; Seo MJ; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2013 Oct; 23(8):1383-92. PubMed ID: 24257552
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
Chung HH; Kwon HW; Kang KW; Park NH; Song YS; Chung JK; Kang SB; Kim JW
Ann Surg Oncol; 2012 Jun; 19(6):1966-72. PubMed ID: 22124757
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer.
Bats AS; Hugonnet F; Huchon C; Bensaid C; Pierquet-Ghazzar N; Faraggi M; Lécuru F
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):474-80. PubMed ID: 22109667
[TBL] [Abstract] [Full Text] [Related]
10. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma.
Iagaru AH; Mittra ES; McDougall IR; Quon A; Gambhir SS
Nucl Med Commun; 2008 Dec; 29(12):1046-51. PubMed ID: 18987524
[TBL] [Abstract] [Full Text] [Related]
11. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging.
Gerbaudo VH; Julius B
Eur J Radiol; 2007 Dec; 64(3):401-5. PubMed ID: 17870274
[TBL] [Abstract] [Full Text] [Related]
